4-溴-3-氯酚 | 13631-21-5

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物 - 酚及其卤化、磺化、硝化或亚硝化衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-溴-3-氯酚
• 中文别名: 4-溴-3-氯苯酚
• 英文名称: 4-bromo-3-chlorophenol
• 英文别名: 3-chloro-4-bromophenol
• CAS: 13631-21-5
• 化学式: C₆H₄BrClO
• 分子量: 207.454
• InChiKey: FQEYHIPPYOSPLF-UHFFFAOYSA-N

物化性质

• 熔点：
  64-66°C
• 沸点：
  267.5±20.0 °C(Predicted)
• 密度：
  1.788±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  在常温常压下稳定，应避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 安全说明：
  S26,S36/37/39
• 海关编码：
  2908199090
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  常温密闭保存，阴凉通风干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-3-chlorophenol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H312: Harmful in contact with skin
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-chlorophenol
CAS number: 13631-21-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H4BrClO
Molecular weight: 207.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-溴-3-氯酚具有广谱杀菌效果，广泛应用于农药、制药、纺织印染和造纸印刷等行业作为原料，也可用于木质家居、果蔬、皮革制品及涂装涂料等产品的杀菌消毒与防腐。

合成方法

将45.7 g（0.466 mol）3-氯酚加入四口瓶中，并在搅拌下分批加入82.74 g（0.465 mol）NBS。在特定温度下进行反应，每隔2小时取样分析，直至3-氯酚的质量分数小于1%时停止反应。随后抽滤，将滤液用水洗涤并分离出油层，进行蒸馏，在37-38℃/0.000 4 MPa条件下收集馏分，即可得到纯度大于98％（气相色谱法测定）的4-溴-3-氯酚产物，其收率可达87%。

反应信息

• 作为反应物：
  描述：

  4-溴-3-氯酚 在 氢气 作用下， 以 正己烷 为溶剂， 35.0 ℃ 、100.0 kPa 条件下， 反应 0.25h， 生成 3-氯苯酚
  参考文献：
  名称：

  二氧化铈载体在 Pd 催化的卤代苯酚加氢脱卤反应中的非无害作用

  摘要：

  卤代苯酚的加氢脱卤 (HDH) 由负载在高表面氧化铈 (Pd/CeO 2 ) 上的钯在温和条件下 (35 °C, 1 atm H 2 )有效催化。NMR、漫反射红外傅里叶变换光谱、拉曼光谱和 XPS 研究以及取代卤代苯的 HDH 动力学的组合表明，反应主要通过一系列酚羟基解离吸附到载体上，C-卤素键氧化加成到钯上，还原消除得到苯酚和卤化氢。-OH 基团在氧化铈载体的氧空位上的解离吸附导致富含电子的中间体，促进了限制周转的还原消除步骤。相比之下，Pd 催化的直接途径没有反应物在载体上的解离吸附，以较慢的速度发生。本研究中获得的机理见解用于修改反应条件，以实现顽固的卤化物（如氟化物和碘化物）的 HDH。

  DOI：

  10.1021/acscatal.1c02716
• 作为产物：
  描述：

  3-氯苯酚 在 溶剂黄146 、 potassium bromide 作用下， 以 水 、 溶剂黄146 为溶剂， 以81%的产率得到4-溴-3-氯酚
  参考文献：
  名称：

  KBr 和 ZnAl-BrO3−-层状双氢氧化物对苯酚进行区域选择性单溴化

  摘要：

  以 KBr 和 ZnAl-BrO3--层状双氢氧化物（缩写为 ZnAl-BrO3--LDHs）作为溴化试剂，成功开发了苯酚的区域选择性单溴化反应。对位点比较有利，如果对位点被占用，则邻位点优先。该反应具有优异的区域选择性、廉价的溴化试剂、反应条件温和、原子经济性高、底物范围广等特点，为溴代苯酚的合成提供了一种有效的方法。

  DOI：

  10.3390/molecules25040914

文献信息

• [EN] BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PFIZER

  公开号：WO2014068527A1

  公开（公告）日：2014-05-08

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

  本文披露了一种与Bruton's酪氨酸激酶（BTK）形成共价键的化合物。公开了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。公开了使用BTK抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症，包括淋巴瘤，以及炎症性疾病或症状的方法。 (化学式I)
• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• Chemical Compounds
  申请人：Brown Alan Daniel

  公开号：US20120010182A1

  公开（公告）日：2012-01-12

  The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z 1 , R a , R b , R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

  该发明涉及磺胺衍生物，其在医学上的应用，含有它们的组合物，其制备方法以及用于这些方法的中间体。 更具体地，该发明涉及公式（I）的新磺胺基Nav1.7抑制剂： 或其药学上可接受的盐，其中Z 1 ，R a ，R b ，R 1 ，R 2 ，R 3 ，R 4 和R 5 如描述中所定义。 Nav 1.7抑制剂在治疗各种疾病，特别是疼痛方面具有潜在用途。
• [EN] TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ALCÉNIQUES TÉTRASUBSTITUÉS ET LEUR UTILISATION
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2016196342A1

  公开（公告）日：2016-12-08

  Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

  本文披露了化合物或其药用可接受盐，并使用这些化合物治疗乳腺癌的方法，通过向需要治疗的受试者施用这些化合物或其药用可接受盐的治疗有效量。乳腺癌可能是ER阳性乳腺癌，需要治疗的受试者可能表达突变的ER-α蛋白。
• [EN] SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS<br/>[FR] PIPERAZINES, (1,4) DIAZEPINES, ET 2,5-DIAZABICYCLO (2.2.1) HEPTANES SUBSTITUES EN TANT QU'ANTAGONISTES DE L'HISTAMINE H1 ET/OU H3 OU ANTAGONISTES INVERSES DE L'HISTAMINE H3
  申请人：GLAXO GROUP LTD

  公开号：WO2004035556A1

  公开（公告）日：2004-04-29

  The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

  本发明涉及具有药理活性的新型哌嗪和氮杂七元环衍生物，其制备方法，含有它们的组合物以及它们在治疗包括阿尔茨海默病在内的神经退行性疾病中的应用。